Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

109.95 -0.08 (-0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
55 56 Next >
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks. 
Via The Motley Fool
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
All of these stocks pay generous dividends that income investors will appreciate. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today
Via Benzinga
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
Analyzing NASDAQ:GILD's Dividend Potential.
Is GILEAD SCIENCES INC (NASDAQ:GILD) a Good Fit for Dividend Investing? 
Via Chartmill
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today
Via Benzinga
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
Via Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week... 
Via Talk Markets
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered... 
Via Benzinga
Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead. 
Via InvestorPlace
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
Via GlobeNewswire
7 Value Stocks to Buy at a 52-Week Low in March
These seven value stocks to buy all trade at low valuations, and have the potential to make big recoveries. 
Via InvestorPlace
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
2 Top Dividend Stocks to Buy Hand Over Fist
Every company faces headwinds eventually. The top ones know how to bounce back. 
Via The Motley Fool
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week... 
Via Talk Markets
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
From Gilead Sciences, Inc.
Via Business Wire
3 Dividend Stocks to Buy Hand Over Fist in March
Income investors might want to load up on these great dividend stocks. 
Via The Motley Fool
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
Exposures Product Safety
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed. 
Via Benzinga
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... 
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.